Miltenyi Biotec is one of the world’s leading providers of products and services for clinical research and cell and gene therapy (CGT). The company is committed to enabling the delivery of new treatment options to patients with unmet medical need. The company has more than 1.800 employees in 25 countries worldwide and its products have been used in more than 50,000 cell therapy procedures.
Our state-of-the-art technologies and products provide integrated workflows for biomedical research and clinical applications, covering sample preparation, cell separation, cell activation, cell transduction and electroporation, cell culture, cell analysis and cell sorting.
We develop validated and tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacture of complex cellular products such as CAR T cells, TCR-transduced T cells, and gene-modified stem cells.
The company offers contract process development and manufacturing services for GMP manufacturing of CGT products based on its recognized platform technologies for cell processing and analytics. It also is a trusted provider of large-scale ancillary materials. Additionally, Miltenyi Biotec designs and develops tailored lentiviral vectors, and manufactures cGMP lentiviral vectors for clinical use.”